Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
|Videos|November 14, 2020
(AAO) Considerations when using anti-VEGF for treating AMD
Author(s)OT Staff Reports
Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.
Advertisement
Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.
Advertisement
Related to this article
Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.
Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Demodex blepharitis: Diagnosis, treatment response, and recurrence
3
Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD
4
SpyGlass Pharma's BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5